Japanese Pharmacology & Therapeutics（JPT）
Vol. 34 Suppl. 2 2006
Opening Remarks
H. Kawasaki
Jpn Pharmacol Ther 2006 34(s2) s91
1. Investigation of the search of selective inhibitors for efflux transporters expressed in human canalicular membrane
S. Matsushima, et al.
Jpn Pharmacol Ther 2006 34(s2) s97-100
2. The in vitro analyses of sterol transport mediated by mouse Abcg5/Abcg8
K. Maeda, et al.
Jpn Pharmacol Ther 2006 34(s2) s101-5
3. Primary investigation of ICG-PDT by femto-second laser
Y. Iwamoto, et al.
Jpn Pharmacol Ther 2006 34(s2) s107-12
4. PPAR agonists inhibit the uptake and efflux transport mediated by multiple transporters
―Substrate dependence, species difference and in vivo relevance―
Y. Tian, et al.
Jpn Pharmacol Ther 2006 34(s2) s113-6
5. Investigation of transporters responsible for the hepatic transport of olmesartan, a novel angiotensin II receptor antagonist
A. Yamada, et al.
Jpn Pharmacol Ther 2006 34(s2) s117-21
【Discussion 1～5】
Jpn Pharmacol Ther 2006 34(s2) s123-5
6. Effects of penicillin G on the biliary excretion of BSP and erythromycin
M. Mikami, et al.
Jpn Pharmacol Ther 2006 34(s2) s127-8
7. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate
― A comparison of human BSEP with rat Bsep―
H. Hayashi, et al.
Jpn Pharmacol Ther 2006 34(s2) s129-36
8. Investigation of influx and efflux transporters involved in the hepatobiliary transport of telmisartan acyglucuronide in humans
N. Ishiguro, et al.
Jpn Pharmacol Ther 2006 34(s2) s137-41
9. Dynamic change of MRP2 localization regulated by the intracellular glutathione (GSH) level
S. Sekine, et al.
Jpn Pharmacol Ther 2006 34(s2) s143-6
10. Physiologically based pharmacokinetic modeling including transporter-mediated membrane transport processes
T. Watanabe, et al.
Jpn Pharmacol Ther 2006 34(s2) s147-50
【Discussion 6～10】
Jpn Pharmacol Ther 2006 34(s2) s151-3
11. Salvage effect of the vascular endothelial growth factor on acute hepatic failure in rats
T. Namisaki, et al.
Jpn Pharmacol Ther 2006 34(s2) s155-9
12. Expression of integrin linked kinase in the rat hepatic stellate cells
T. Ikegami, et al.
Jpn Pharmacol Ther 2006 34(s2) s161-3
13. Beneficial effects of lamivudine in hepatitis B related hepatocellular carcinoma
M. Koda, et al.
Jpn Pharmacol Ther 2006 34(s2) s165-9
14. Genetic polymorphisms of matrix matalloproteinases and Interleukin-1β with the progression of liver fibrosis in chronic hepatitis C
M. Mandai, et al.
Jpn Pharmacol Ther 2006 34(s2) s171-4
15. Portal pressure response to olmesaltan medoxomil in patients with cirrhosis
H. Hidaka, et al.
Jpn Pharmacol Ther 2006 34(s2) s175-8
【Discussion 11～15】
Jpn Pharmacol Ther 2006 34(s2) s179-2
SH. Kawa, et al.
Jpn Pharmacol Ther 2006 34(s2) s183-7
17. Evaluation of the stage of non-alcoholic steatohepatitis (NASH)
C. Koreeda, et al.
Jpn Pharmacol Ther 2006 34(s2) s189-5
19. Molecular defects in the hydroxymethylbilane synthase gene in Japanese patients with acute intermittent porphyria
N. Maeda, et al.
Jpn Pharmacol Ther 2006 34(s2) s197-201
20. Differential diagnosis of erythropoietic protoporphyria
―Two cases of xeroderma pigmentosum―
Y. Horie, et al.
Jpn Pharmacol Ther 2006 34(s2) s203-5
【Discussion 16～20】
Jpn Pharmacol Ther 2006 34(s2) s207-8
Closing Remarks
S. Kokubu
Jpn Pharmacol Ther 2006 34(s2) s209